Biogen to Present Alzheimer’s Portfolio Data at CTAD 2026
Biogen said it will present new data across its Alzheimer’s disease portfolio at CTAD 2026. The body also mentions diranersen as a late-breaking item.
Biogen said it will present new data across its Alzheimer’s disease portfolio at CTAD 2026. The body also mentions diranersen as a late-breaking item.